

# Hereditary Transthyretin Amyloidosis (HATTR) Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/H46E96AAFF00EN.html>

Date: January 2022

Pages: 61

Price: US\$ 3,250.00 (Single User License)

ID: H46E96AAFF00EN

## Abstracts

Hereditary Transthyretin Amyloidosis (HATTR) is caused by the misfolding of protein monomers derived from the tetrameric protein transthyretin (TTR). Mutations in the gene for TTR frequently result in instability of TTR and subsequent fibril formation. HATTR can be sub-classified into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). The deposition of TTR amyloid fibrils in various tissues leads to ATTR, including Familial ATTR (hereditary ATTR) and non-hereditary ATTR types. Familial ATTR is a rare disorder with unequal distribution all around the world.

This report contains market size and forecasts of Hereditary Transthyretin Amyloidosis (HATTR) in Global, including the following market information:

Global Hereditary Transthyretin Amyloidosis (HATTR) Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Hereditary Transthyretin Amyloidosis (HATTR) market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Oral Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hereditary Transthyretin Amyloidosis (HATTR) include

Pfizer, Alnylam Pharmaceuticals, Akcea Therapeutics, Prothena, Lonis Pharmaceuticals, Eidos Therapeutics and Corino Therapeutics Inc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hereditary Transthyretin Amyloidosis (HATTR) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hereditary Transthyretin Amyloidosis (HATTR) Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Hereditary Transthyretin Amyloidosis (HATTR) Market Segment Percentages, by Type, 2021 (%)

Oral

Subcutaneous Injection

Others

Global Hereditary Transthyretin Amyloidosis (HATTR) Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Hereditary Transthyretin Amyloidosis (HATTR) Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Others

Global Hereditary Transthyretin Amyloidosis (HATTR) Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

## Global Hereditary Transthyretin Amyloidosis (HATTR) Market Segment Percentages, By Region and Country, 2021 (%)

### North America

US

Canada

Mexico

### Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

### Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hereditary Transthyretin Amyloidosis (HATTR) revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Hereditary Transthyretin Amyloidosis (HATTR) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer

Alnylam Pharmaceuticals

Akcea Therapeutics

Prothena

Lonis Pharmaceuticals

Eidos Therapeutics

Corino Therapeutics Inc

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Hereditary Transthyretin Amyloidosis (HATTR) Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR) OVERALL MARKET SIZE**

- 2.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size: 2021 VS 2028
- 2.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

### **3 COMPANY LANDSCAPE**

- 3.1 Top Hereditary Transthyretin Amyloidosis (HATTR) Players in Global Market
- 3.2 Top Global Hereditary Transthyretin Amyloidosis (HATTR) Companies Ranked by Revenue
- 3.3 Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue by Companies
- 3.4 Top 3 and Top 5 Hereditary Transthyretin Amyloidosis (HATTR) Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Hereditary Transthyretin Amyloidosis (HATTR) Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Hereditary Transthyretin Amyloidosis (HATTR) Players in Global Market
  - 3.6.1 List of Global Tier 1 Hereditary Transthyretin Amyloidosis (HATTR) Companies

### 3.6.2 List of Global Tier 2 and Tier 3 Hereditary Transthyretin Amyloidosis (HATTR) Companies

## 4 MARKET SIGHTS BY PRODUCT

### 4.1 Overview

4.1.1 by Type - Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size Markets, 2021 & 2028

4.1.2 Oral

4.1.3 Subcutaneous Injection

4.1.4 Others

4.2 By Type - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue & Forecasts

4.2.1 By Type - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2017-2022

4.2.2 By Type - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2023-2028

4.2.3 By Type - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2017-2028

## 5 SIGHTS BY APPLICATION

### 5.1 Overview

5.1.1 By Application - Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.1.4 Others

5.2 By Application - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue & Forecasts

5.2.1 By Application - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2017-2022

5.2.2 By Application - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2023-2028

5.2.3 By Application - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2017-2028

## 6 SIGHTS BY REGION

6.1 By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2021 & 2028

6.2 By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue & Forecasts

6.2.1 By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2017-2022

6.2.2 By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2023-2028

6.2.3 By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2017-2028

6.3.2 US Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.3.3 Canada Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.3.4 Mexico Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2017-2028

6.4.2 Germany Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.4.3 France Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.4.4 U.K. Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.4.5 Italy Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.4.6 Russia Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.4.7 Nordic Countries Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.4.8 Benelux Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2017-2028

6.5.2 China Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.5.3 Japan Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.5.4 South Korea Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.5.5 Southeast Asia Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.5.6 India Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Hereditary Transthyretin Amyloidosis (HATTR)

## Revenue, 2017-2028

6.6.2 Brazil Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.6.3 Argentina Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

## 6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR)

## Revenue, 2017-2028

6.7.2 Turkey Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.7.3 Israel Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.7.4 Saudi Arabia Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

6.7.5 UAE Hereditary Transthyretin Amyloidosis (HATTR) Market Size, 2017-2028

## 7 PLAYERS PROFILES

### 7.1 Pfizer

7.1.1 Pfizer Corporate Summary

7.1.2 Pfizer Business Overview

7.1.3 Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings

7.1.4 Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global Market (2017-2022)

7.1.5 Pfizer Key News

### 7.2 Alnylam Pharmaceuticals

7.2.1 Alnylam Pharmaceuticals Corporate Summary

7.2.2 Alnylam Pharmaceuticals Business Overview

7.2.3 Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings

7.2.4 Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global Market (2017-2022)

7.2.5 Alnylam Pharmaceuticals Key News

### 7.3 Akcea Therapeutics

7.3.1 Akcea Therapeutics Corporate Summary

7.3.2 Akcea Therapeutics Business Overview

7.3.3 Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings

7.3.4 Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global Market (2017-2022)

7.3.5 Akcea Therapeutics Key News

### 7.4 Prothena

- 7.4.1 Prothena Corporate Summary
- 7.4.2 Prothena Business Overview
- 7.4.3 Prothena Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings
- 7.4.4 Prothena Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global Market (2017-2022)
- 7.4.5 Prothena Key News
- 7.5 Lonis Pharmaceuticals
  - 7.5.1 Lonis Pharmaceuticals Corporate Summary
  - 7.5.2 Lonis Pharmaceuticals Business Overview
  - 7.5.3 Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings
  - 7.5.4 Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global Market (2017-2022)
  - 7.5.5 Lonis Pharmaceuticals Key News
- 7.6 Eidos Therapeutics
  - 7.6.1 Eidos Therapeutics Corporate Summary
  - 7.6.2 Eidos Therapeutics Business Overview
  - 7.6.3 Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings
  - 7.6.4 Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global Market (2017-2022)
  - 7.6.5 Eidos Therapeutics Key News
- 7.7 Corino Therapeutics Inc
  - 7.7.1 Corino Therapeutics Inc Corporate Summary
  - 7.7.2 Corino Therapeutics Inc Business Overview
  - 7.7.3 Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Major Product Offerings
  - 7.7.4 Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global Market (2017-2022)
  - 7.7.5 Corino Therapeutics Inc Key News

## **8 CONCLUSION**

## **9 APPENDIX**

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Hereditary Transthyretin Amyloidosis (HATTR) Market Opportunities & Trends in Global Market

Table 2. Hereditary Transthyretin Amyloidosis (HATTR) Market Drivers in Global Market

Table 3. Hereditary Transthyretin Amyloidosis (HATTR) Market Restraints in Global Market

Table 4. Key Players of Hereditary Transthyretin Amyloidosis (HATTR) in Global Market

Table 5. Top Hereditary Transthyretin Amyloidosis (HATTR) Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Share by Companies, 2017-2022

Table 8. Global Companies Hereditary Transthyretin Amyloidosis (HATTR) Product Type

Table 9. List of Global Tier 1 Hereditary Transthyretin Amyloidosis (HATTR) Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Hereditary Transthyretin Amyloidosis (HATTR) Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Hereditary Transthyretin Amyloidosis (HATTR) Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue

(US\$, Mn), 2023-2028

Table 20. By Country - North America Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2023-2028

Table 30. Pfizer Corporate Summary

Table 31. Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Product Offerings

Table 32. Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Revenue (US\$, Mn), (2017-2022)

Table 33. Alnylam Pharmaceuticals Corporate Summary

Table 34. Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Product Offerings

Table 35. Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Revenue (US\$, Mn), (2017-2022)

Table 36. Akcea Therapeutics Corporate Summary

Table 37. Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Product Offerings

Table 38. Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Revenue (US\$, Mn), (2017-2022)

Table 39. Prothena Corporate Summary

Table 40. Prothena Hereditary Transthyretin Amyloidosis (HATTR) Product Offerings

Table 41. Prothena Hereditary Transthyretin Amyloidosis (HATTR) Revenue (US\$, Mn), (2017-2022)

|                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------|
| Table 42. Lonis Pharmaceuticals Corporate Summary                                                                 |
| Table 43. Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR)<br>Product Offerings                 |
| Table 44. Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR)<br>Revenue (US\$, Mn), (2017-2022)   |
| Table 45. Eidos Therapeutics Corporate Summary                                                                    |
| Table 46. Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Product<br>Offerings                    |
| Table 47. Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Revenue<br>(US\$, Mn), (2017-2022)      |
| Table 48. Corino Therapeutics Inc Corporate Summary                                                               |
| Table 49. Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR)<br>Product Offerings               |
| Table 50. Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR)<br>Revenue (US\$, Mn), (2017-2022) |

## List Of Figures

### LIST OF FIGURES

Figure 1. Hereditary Transthyretin Amyloidosis (HATTR) Segment by Type in 2021

Figure 2. Hereditary Transthyretin Amyloidosis (HATTR) Segment by Application in 2021

Figure 3. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Hereditary Transthyretin Amyloidosis (HATTR) Revenue in 2021

Figure 8. By Type - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2017-2028

Figure 9. By Application - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2017-2028

Figure 10. By Region - Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2017-2028

Figure 11. By Country - North America Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2017-2028

Figure 12. US Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2017-2028

Figure 16. Germany Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 17. France Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2017-2028

Figure 24. China Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 28. India Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2017-2028

Figure 30. Brazil Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share, 2017-2028

Figure 33. Turkey Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Hereditary Transthyretin Amyloidosis (HATTR) Revenue, (US\$, Mn), 2017-2028

Figure 37. Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Revenue

Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Prothena Hereditary Transthyretin Amyloidosis (HATTR) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

## I would like to order

Product name: Hereditary Transthyretin Amyloidosis (HATTR) Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/H46E96AAFF00EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H46E96AAFF00EN.html>